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Abstract
Background: Limited data is available on kidney function in HIV-infected children in sub-Saharan Africa. In
addition, malnutrition in these children further reduces the utility of diagnostic methods such as creatinine-based
estimates of glomerular filtration rate. We determined the serum cystatin C level and estimated glomerular filtration
rate of 60 antiretroviral-naïve, HIV-infected children and 60 apparently healthy age and sex matched children.
Methods: Serum cystatin C level was measured using enzyme-linked immunosorbent assay technique, while
glomerular filtration rate was estimated using Filler’s serum cystatin C formula. Student t test, Mann Whitney U test,
Pearson chi square and Fisher’s exact test were used, where appropriate, to test difference between groups.
Results: Compared to the controls, the HIV-infected group had significantly higher median (interquartile range)
serum cystatin C levels {0.77 (0.29) mg/l versus 0.66 (0.20) mg/l; p = 0.025} and a higher proportion of children
with serum cystatin C level >1 mg/l {10 (16.7%) versus one (1.7%); p = 0.004}. The HIV-infected children had a
mean (± SD) eGFR of 96.8 (± 36.1) ml/min/1.73 m
2 compared with 110.5 (± 27.8) ml/min/1.73 m
2 in the controls
(p = 0.021). After controlling for age, sex and body mass index, only the study group (HIV infected versus control)
remained a significant predictor of serum cystatin C level (b = -0.216, p = 0.021). The proportion of HIV-infected
children with eGFR <60 ml/min/1.73 m
2 was eight (13.3%) versus none (0%) in the control group (p = 0.006).
However, the serum cystatin C level, eGFR and proportions of children with serum cystatin C level >1 mg/l and
eGFR <60 ml/min/1.73 m
2 were not significantly different between the HIV-infected children with advanced
disease and those with milder disease.
Conclusions: HIV-infected children in Nigeria have higher serum cystatin C level and lower eGFR compared to age
and sex matched controls.
Background
Although sub-Saharan Africa has the largest number of
children living with HIV, little is known about the pre-
valence of HIV-related kidney disease in these children
despite the recognition of HIV infection as a strong
initiation risk factor for kidney disease [1,2]. The dearth
of resources for care of children with kidney diseases
and the limited choice of antiretroviral drugs in Africa
underline a need to not only accurately assess
glomerular filtration rate (GFR) in these children, but to
do so early if their kidney function is to be preserved.
However, the well-known method of assessment of
kidney function using creatinine-based formulae is
fraught with several shortcomings in the general popu-
lation [3,4] and particularly in HIV-infected persons
[5]. Notably, creatinine clearance is significantly influ-
enced by tubular secretion [3,4] and the serum creati-
nine level is affected by non-renal factors, such as diet,
race and lean mass. Also, the only method widely
available for clinical analysis of creatinine in Nigeria is
the modified kinetic Jaffe method with its accompany-
ing limitations [6].
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sub-Saharan Africa, especially in those living with HIV/
AIDS [7]. This further reduces the usefulness of serum
creatinine-based formulae in the routine assessment of
kidney function and has implications for early detection
of impaired kidney function in these children [8].
Conversely, cystatin C, a 13 kilo dalton 120-amino
acid peptide produced at a fairly constant rate by the
house-keeping genes of all nucleated cells, has been
shown to be a better measure of glomerular filtration
[8-10]. Compared to creatinine, it is less affected by
non-glomerular factors, such as lean mass, diet and tub-
ular secretion [3,9,10]. Similarly, cystatin C-based
formulae for estimation of GFR closely mirror gold-
standard measures of GFR and reflect changes in GFR
earlier than creatinine-based formulae [8,11]. Of the sev-
eral cystatin C-based formulae for GFR, the one pro-
posed by Filler et al [11], developed from a study
involving children between the ages of one year and 18
years, has been shown to be of greater precision, lower
bias and higher accuracy than the creatinine-based
formula of Schwartz and most other cystatin C-based
formulae [12].
In the present study, we compared kidney function in
children with and without HIV infection attending the
outpatient clinics of the Lagos University Teaching Hos-
pital using the serum level of cystatin C, and estimated
GFR using Filler’s cystatin C-based formula.
Methods
Study setting and population
The study was done between January and June 2008,
and was approved by the Hospital’s Research and Ethics
Committee. It was a cross-sectional observational study
of HIV-infected children attending the Paediatric Special
Clinic of the Lagos University Teaching Hospital. The
clinic, which provides comprehensive antiretroviral ther-
apy, is largely supported by the US President’sE m e r -
gency Plan For AIDS Relief (PEPFAR).
The diagnosis of HIV infection was based on a docu-
mentary evidence of HIV infection using the enzyme-
linked immunosorbent assay (ELISA) test and confirmed
by western blot technique; for those who were diag-
nosed before the age of 18 months, diagnosis was based
on positive HIV DNA PCR tests on two separate sam-
ples. All consecutive HIV-infected antiretroviral-naïve
children, aged 18 months to 16 years and who met the
study criteria, were eligible. Excluded from the study
were children: with sickle cell disease, with cardiac dis-
ease or previously confirmed kidney disease; those hos-
pitalized within the past two weeks; those with the
presence of any illness severe enough to require hospita-
lization; those with diarrhoea; and those who had used
systemic steroids within the past one week.
During the study time frame, 71 antiretroviral-naïve
HIV-infected children attended the Paediatric Special
Clinic, and 11 were excluded: six needed immediate
hospitalization for acute illnesses; three samples were
discarded because of haemolysis; and two had incom-
plete CD4+ cell count or percentage results. The
excluded children were not different in age and sex
distribution from those enrolled. A one-to-one age and
sex matched pairing was done from a pool of HIV-
uninfected children. Age matching was done to the
nearest half year for those ≤ 5 years and to the nearest
year for those older than five years. Where more than
one control existed, a ballot was taken. The matching
was done prior to analysis of the sample for serum
cystatin C to avoid bias.
The controls were ambulatory, apparently healthy chil-
dren recruited while attending other clinics of the hospi-
tal: respiratory clinic (n = 17, those with bronchial
asthma, but not receiving systemic steroid or those
being followed up after hospitalization for bronchopneu-
monia); neurology clinic (n = 27, children with one or
more episodes of seizure referred to the clinic, but not
yet on anticonvulsants); surgical clinic (n = 11, children
prior to or after herniotomy, post appendicectomy); and
ear, nose and throat clinic (n = 5, those with speech or
hearing disorders).
No incentive to participate in the study was offered to
the caregivers. The inclusion and exclusion criteria were
the same for both groups of participants, except for the
absence of HIV infection in the control group.
Data collection
After informed consent, relevant clinical and demo-
graphic data were obtained by interviewing each care-
giver and physically examining each child. The clinical
notes and chest X-rays of each participating child with
HIV infection were also reviewed for a diagnosis of
tuberculosis. The data obtained were used in staging the
HIV disease, according to the revised World Health
Organization (WHO) paediatric clinical staging criteria
[13].
About 5 ml of blood was obtained from each partici-
pating child. Out of this, 2 ml was allowed to clot, and
the resulting serum after centrifugation was frozen at
-80°C until analysis. The remaining 3 ml of blood was
used for haemoglobin electrophoresis and CD4+ cell
count or percentage in the HIV-infected children and in
the controls for haemoglobin electrophoresis and detec-
tion of HIV antibodies (using Determine HIV rapid kit™
manufactured by Abbot Japan Co Ltd for Inverness
Medical Japan Co Ltd).
I nb a t c h e so f3 0s a m p l e s ,t he serum cystatin C was
measured by a sandwich enzyme-linked immunosorbent
assay for the quantitative measurement of human
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Laboratorni medicina a.s, Czech Republic. The intra-
assay co-efficient of variation (CV) for the quality
controls (QC) were as follows: low QC, 3.9%; high QC,
3.1%. The inter-assay CV were as follows: low QC, 6.8%
and high QC, 11.8%.
The estimated glomerular filtration rate (eGFR)
(ml/min/1.73 m
2) was derived using a cystatin C-based
formula as proposed by Filler et al [11], i.e.
Log(GFR) 1.962 {1.123*log(1/cystatinC)} =+ ,
where 1/cystatin C is the reciprocal of the concentra-
tion of serum cystatin C in mg/l.
Advanced HIV disease was defined clinically as WHO
Clinical Stage 3 disease or Clinical Stage 4 disease, or
immunologically as CD4+ cell count <350 cells/mm
3 (in
those ≥ 5 years old) or CD4 percentage 20% (in those
younger than five years). Of the 35 children with
advanced HIV disease, 10 (28.6%) were classified based
on WHO clinical criteria only, 10 (28.6%) on immunolo-
gical criteria only, and 15 (42.9%) on both clinical and
immunological criteria.
Statistical analysis
T h ed a t aw e r ea n a l y z e du s i n gS P S Sv e r s i o n1 4 . 0( S P S S
for Windows Inc., Chicago, IL, USA) statistical software.
Anthropometric z scores were calculated using the
WHO AnthroPlus software developed using the WHO
Child Growth Standards and the WHO Reference 2007
[14]. Continuous data were summarized as mean (± SD)
and median (inter-quartile range) for parametric and
non-parametric data, respectively, while categorical data
were represented as proportions. Pearson’sC h is q u a r e
or Fisher’s exact test was used to compare categorical
data, while Mann Whitney U test and Student’stt e s t
were used to analyse the non-parametric (serum cystatin
C) and parametric (eGFR) data, respectively.
A multiple linear regression, simultaneously account-
ing for weight, height, age, gender and study group
(HIV positive versus control) with log transformed
cystatin C as the dependent variable, was performed
(Model 1). A separate model (Model 2) was tested,
using age, sex, study group and body mass index (BMI)
as independent variables to avoid colinearity between
BMI and weight and height. Differences, correlations
(Spearman’s) and regression coefficient between vari-
ables were considered significant if the p value was less
than 0.05.
Results
Table 1 displays the results of the HIV-infected children
compared with the controls. Sixty children with HIV
infection and 60 apparently healthy, HIV-uninfected
children were studied. The median age was 5.5 (5.2)
years in the HIV-infected group and 5.3 (5.2) years in
the control. The HIV-infected children were leaner
(BMI z score -1.07 vs. -0.31; p = 0.048), shorter (HAZ
score -1.00 vs. 0.05; p = 0.000) and weighed less (WAZ
score -1.30 vs. -0.15; p = 0.000) compared with children
in the control group.
The median serum cystatin C level was 0.77 (0.29)
mg/l in the HIV-infected group compared with 0.66
(0.20) mg/l in the control (p value = 0.025).
There was no statistically significant difference in the
cystatin C level of the controls recruited from the var-
ious clinics (result not shown). Similarly, 10 (16.7%)
children with HIV infection compared with one in
the control group (1.7%) had a serum cystatin C level
>1.0 mg/l (p value = 0.004). The mean eGFR was
96.8 (±36.1) ml/min/1.73 m
2 in the children with HIV
infection and was significantly lower than the eGFR of
110.5 (± 27.8) ml/min/1.73 m
2 in the control group
(p = 0.021). Conversely, eight (13.3%) of the children
with HIV infection, compared with none in the control
group, had an eGFR less than 60 ml/min/1.73 m
2
(p = 0.006).
Table 2 displays the characteristics of the children
with HIV infection. In children younger than five years
Table 1 Demographic and kidney-related characteristics
of study participants.
Characteristics HIV-infected
children
(n = 60)
Control
(n = 60)
p
value
Age (years)
Median (IQR) 5.5 (5.2) 5.3 (5.2) 0.990
a
<5 years, n (%) 28 (46.7) 26 (43.3)
Male gender, n% 35 (58.3) 35 (58.3) 1.00
b
Weight
Median (kg) 15.3 (8) 19.8 (11.9) 0.026
a
WAZ score -1.30 -0.15 0.000
a
Length/height
Median (cm) 107 (25) 115 (36) 0.181
a
HAZ score -1.00 0.05 0.000
a
BMIZ score -1.07 -0.31 0.048
a
Blood pressure, mean
(mmHG)
66.9 (10.9) 64.9 (7.7) 0.223
c
Serum cystatin C
median (mg/l) 0.77 (0.29) 0.66 (0.20) 0.025
a
>1.0 mg/l, no. (%) 10 (16.7) 1 (1.7) 0.004
b
Estimated GFR
mean (ml/min/1.73 m
2) 96.8 (36.1) 110.5
(27.8)
0.021
c
<60 ml/min/1.73 m
2, no.
(%)
8 (13.3) 0 (0) 0.006
b
WAZ: weight for age z score; HAZ: height for age z score; BMIZ: Body mass
index z score;
aMann-Whitney U test;
bPearson’s Chi square test;
c Student t
test; IQR: interquartile range
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with advanced disease versus 25.1% in those with less
advanced disease. In children five years or older, the
median CD4 count was 343 cells/mm
3 in those with
advanced disease versus 568 cells/mm
3 in those with
less advanced disease (p = 0.002). There was no signifi-
cant difference in cystatin C level, eGFR and propor-
tions with serum cystatin C >1 mg/l and eGFR <60 ml/
min/1.73 m
2 between children with advanced disease
versus the less advanced disease, although most mea-
sures of kidney function were worse in the advanced
disease group.
The correlation of weight, length, BMI and age with
serum cystatin C was small and not significant in both
groups of children (Figure 1 &2). In multiple linear
r e g r e s s i o n ,t h ev a r i a t i o ni nc y s t a t i nCa se x p l a i n e db y
both models was small and only reached significant pro-
portion in Model 2 (model including BMI), Table 3 and
Table 4. Only the study group (HIV infected versus con-
trol) remained a significant predictor of cystatin C after
controlling for other variables, including BMI.
Discussion
The study documented a high level of serum cystatin C
and significant reduction in eGFR in HIV-infected chil-
dren stable enough to attend the outpatient clinic of the
Lagos University Teaching Hospital. Though the mean
eGFR was within the normal range, more HIV-infected
children than controls had eGFR less than 60 ml/min/
1.73 m
2. Similarly, more HIV-infected children than
controls had a serum cystatin level greater than 1 mg/l,
a level associated with an increased risk of death from
cardiovascular and kidney diseases in elderly adults
[15,16].
The elevated serum cystatin C level in HIV-infected
children in this study is consistent with the reports of
the Fat Redistribution and Metabolic Change in HIV
infection (FRAM) study [5], the Nutrition for Healthy
Living Study [8] and Jaroszewicz et al [17]. The high
serum cystatin C level among the children with HIV
infection may imply a significant reduction in glomeru-
lar filtration because, unlike creatinine, glomerular filtra-
tion is the only significant means of the plasma
clearance of cystatin C [10,18]. HIV infection, by indu-
cing a glomerulopathy (as exemplified in HIV-associated
nephropathy), results in a reduction in the plasma clear-
ance of substance by glomerular filtration [2].
In agreement with results from the majority of studies
in this field [9,19-21], there was no significant correla-
tion of serum cystatin C with age, sex, length, BMI and
weight. Only the study group remained a significant pre-
dictor of cystatin C. This is consistent with the report of
a recent study in children [21], which did not find any
association between cystatin C and body mass, although
studies involving adults have revealed varied results
[19,22,23].
Our finding of high prevalence of eGFR less than
60 ml/min/1.73 m
2 in the HIV-infected children is
consistent with a previous study [24], which documented
a proteinuria prevalence of 20.5% among this clinic
cohort of HIV-infected children. Similarly, a large body
of research [25-27] have documented high prevalence of
kidney diseases in HIV-infected persons. Jones et al [8]
and Wools-Kaloustian and colleagues [27] reported pre-
valence of GFR less than 60 ml/min/1.73 m
2 between
11.5% and 15.2%, respectively; these findings are similar
to ours.
The high level of serum cystatin C and prevalence of
GFR less than 60 ml/min/1.73 m
2 in this cohort of
HIV-infected children in Nigeria supports the associa-
tion between HIV infection and kidney disease [2,25],
and implies that HIV-related kidney disease may be as
common in African children as in children residing in
other regions of the world [24-26].
The significant reduction in GFR among HIV-infected
children stable enough to attend outpatient clinics prob-
ably indicates a chronic, rather than a rapidly evolving,
reduction in GFR. In sub-Saharan Africa, where the bur-
den of HIV infection is high and the dearth of resources
f o rk i d n e yc a r ep r o f o u n d ,t h eh i g hp r e v a l e n c eo f
Table 2 Serum cystatin C and eGFR of children with different stages of HIV disease.
Variables Stage of HIV disease p value
Advanced
n=3 5
Not advanced
n=2 5
HIV-related variables:
For <5 years, CD4%, median (IQR) 12.6 (8.2) 25.1 (5.2) 0.000
a
For ≥ 5 years, CD4 count/mm
3, median(IQR) 343 (488) 568 (507) 0.002
a
Serum cystatin C, median (mg/l) 0.79 (0.35) 0.76 (0.24) 0.196
a
Cystatin C >1.0 mg/l, no. (%) 8 (22.9) 2 (8) 0.119
b
eGFR, mean (ml/min/1.73 m
2) 97.3 (4.2) 96.2 (23.6) 0.904
c
eGFR <60 ml/min/1.73 m
2 no. (%) 6 (17.1) 2 (8) 0.265
b
a Mann Whitney U test;
b Pearson’s Chi square test;
c Student’stt e s t
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mented in this study warrants early detection of kidney
involvement in HIV infection and institution of mea-
sures that may halt progression to end-stage kidney
disease.
In donor-driven programmes (prevalent in the region)
where the choice of antiretroviral drugs is limited, the
high proportion of HIV-infected children with GFR less
than 60 ml/min/1.73 m
2, a GFR level that may require
adjustment of drug dosages, is of concern. It also
requires caution when rolling out antiretroviral drug
regimens, including indinavir, adefovir and tenofovir
that affect kidney function [5,28].
The lack of a significant difference between the GFR
in HIV-infected children with advanced stage of HIV
disease compared with those with less advanced stage
could be due to the criteria chosen for classification of
HIV disease into “advanced” and “not advanced” groups.
Also, the small sample size could have underpowered
the detection of any significant difference in eGFR and
serum cystatin C.
The inclusion of only antiretroviral-naïve, HIV-
infected children is a strength of this study because it
provided an opportunity to document the prevalence of
reduced GFR not confounded by the effects of highly
active antiretroviral therapy (HAART). To our
Figure 1 Correlation of serum cystatin C with age and weight in HIV-infected children (A & C) and in the controls (B & D).
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Page 5 of 8Figure 2 Correlation of serum cystatin C with length and BMI in HIV-infected children (E & G) and in the controls (F & H).
Table 3 Multiple linear regression model simultaneously accounting for age, gender, length, weight and study group
(Model 1).
Independent variables Unstandardized coefficient Standardized coefficient p value
Constant -0.067 - 0.686
Age 0.016 0.341 0.173
Gender -0.009 -0.03 0.741
Length -0.001 -0.07 0.817
Weight -0.003 -0.205 0.301
Study group -0.055 -0.186 0.065
R
2 = 0.089, p = 0.057
Table 4 Multiple linear regression model simultaneously accounting for age, gender, study group and BMI (Model 2).
Independent variables Unstandardized coefficient Standardized coefficient p value
Constant -0.019 - 0.844
Age 0.006 0.129 0.155
Gender -0.010 -0.034 0.711
BMI -0.007 0.111 0.252
Study group -0.063 -0.216 0.0210
R
2 = 0.083 p.value = 0.039
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reports [5,8,17] of cystatin C or cystatin C-based eGFR
in HIV-infected persons included those on HAART
with regimens consisting of tenofovir and indinavir, and
the reported increase in serum cystatin C in these stu-
dies may have been confounded by the use of these
drugs [5,28]. We also analyze serum cystatin C in a sin-
gle laboratory, which helps to reduce systematic error.
Our limitations include estimation of GFR, rather than
actual measurement and unavailability of C-reactive pro-
tein, which has been shown to positively correlate with
cystatin C level [29]. However, a previous report [24] of
high prevalence of kidney disease in this clinic cohort of
HIV-infected children strengthens the validity of our
finding.
In conclusion, we have reported an elevated serum
cystatin C level unaffected by BMI and a high preva-
lence of GFR <60 ml/min/1.73 m
2 in antiretroviral-
naïve, HIV-infected children attending the outpatient
clinic of the Lagos University Teaching Hospital.
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